Abstract
While utility of ovarian suppression in prevention of hormone receptor positive (HR+) breast cancer recurrence is well established, debate exists regarding methods of suppression. The two most utilized methods in premenopausal women are bilateral salpingo-oophorectomy (BSO) or gonadotropin hormone releasing (GnRH) agonist, both in combination with aromatase inhibitor (AI) or tamoxifen. These patients are often referred to gynecologic surgeons for discussion of GnRH or BSO, but there is scant data to guide counseling.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
